BUFFALO — Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, Wednesday announced the pricing of its initial public offering of 6 million shares of its common stock at a price of $11 per share.
In addition, Athenex has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price. The company’s shares began trading on The NASDAQ Global Select Market on Wednesday under the ticker symbol “ATNX.”
The offering is expected to close on Monday subject to customary closing conditions.
Credit Suisse Securities (USA) LLC, Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering.
ICBC International Securities Limited is acting as co-manager.
The biopharmaceutical company is in the process of constructing a drug manufacturing plant in Dunkirk, which could create up to 900 jobs.
A registration statement relating to the securities being sold in this offering was declared effective by the Securities and…